Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis

IF 4.1 2区 医学 Q1 PSYCHIATRY General hospital psychiatry Pub Date : 2024-06-11 DOI:10.1016/j.genhosppsych.2024.06.003
Naveen Chandrashekar Hegde , Archana Mishra , Rituparna Maiti , Biswa Ranjan Mishra , Debadatta Mohapatra , Anand Srinivasan
{"title":"Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis","authors":"Naveen Chandrashekar Hegde ,&nbsp;Archana Mishra ,&nbsp;Rituparna Maiti ,&nbsp;Biswa Ranjan Mishra ,&nbsp;Debadatta Mohapatra ,&nbsp;Anand Srinivasan","doi":"10.1016/j.genhosppsych.2024.06.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Antipsychotic-induced weight gain (AIWG) is a significant but frequently neglected adverse effect of first- and second-generation antipsychotic therapy, which may lead to cardiovascular disturbances. The present network meta-analysis (NMA) was conducted to evaluate and compare the effects of available treatment options in antipsychotic-induced weight gain (AIWG).</p></div><div><h3>Methods</h3><p>The data was extracted from 68 relevant clinical trials after a literature search on MEDLINE/PubMed, Embase, Scopus, Cochrane databases and clinical trial registries. Random-effects Bayesian NMA was done to pool the effects across the interventions for the change in body weight from baseline. A network graph was built, a consistency model was run, node split analysis was performed, treatments were ranked as per the SUCRA score and meta-regression was done for the duration of therapy, baseline body weight and treatment strategy as the predictor variables. Finally, the results were sorted based on the certainty of evidence.</p></div><div><h3>Results</h3><p>The drugs showing significant reduction in body weight in order of magnitude of effect size include sibutramine 10 mg (−8.0 kg; −16. to −0.21), metformin 750 mg + lifestyle modification (−7.5 kg; −12 to −2.8), topiramate 200 mg (−7 kg; −10 to −3.4), metformin 750 mg (−5.7 kg; −9.3 to −2.1), topiramate 100 mg (−5.7 kg; −8.8 to −2.5), topiramate 50 mg (−5.2 kg; −10 to −0.57), liraglutide 1.8 mg (−5.2 kg; −10., −0.080), sibutramine 15 mg (−4.5 kg; −8.9 to −0.59), nizatidine 300 mg (−3.0 kg; −5.9 to −0.23) and metformin 1000 mg (−2.3 kg; −4.6 to −0.0046). There was no effect of duration of follow-up, baseline body weight and, preventive versus therapeutic strategy on weight reduction in AIWG.</p></div><div><h3>Conclusion</h3><p>Metformin 750 mg with lifestyle modification was the most effective treatment for AIWG, followed by topiramate 200 mg, metformin 750 mg, and topiramate 100 mg with moderate certainty of evidence.</p></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"90 ","pages":"Pages 12-21"},"PeriodicalIF":4.1000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General hospital psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163834324001427","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Antipsychotic-induced weight gain (AIWG) is a significant but frequently neglected adverse effect of first- and second-generation antipsychotic therapy, which may lead to cardiovascular disturbances. The present network meta-analysis (NMA) was conducted to evaluate and compare the effects of available treatment options in antipsychotic-induced weight gain (AIWG).

Methods

The data was extracted from 68 relevant clinical trials after a literature search on MEDLINE/PubMed, Embase, Scopus, Cochrane databases and clinical trial registries. Random-effects Bayesian NMA was done to pool the effects across the interventions for the change in body weight from baseline. A network graph was built, a consistency model was run, node split analysis was performed, treatments were ranked as per the SUCRA score and meta-regression was done for the duration of therapy, baseline body weight and treatment strategy as the predictor variables. Finally, the results were sorted based on the certainty of evidence.

Results

The drugs showing significant reduction in body weight in order of magnitude of effect size include sibutramine 10 mg (−8.0 kg; −16. to −0.21), metformin 750 mg + lifestyle modification (−7.5 kg; −12 to −2.8), topiramate 200 mg (−7 kg; −10 to −3.4), metformin 750 mg (−5.7 kg; −9.3 to −2.1), topiramate 100 mg (−5.7 kg; −8.8 to −2.5), topiramate 50 mg (−5.2 kg; −10 to −0.57), liraglutide 1.8 mg (−5.2 kg; −10., −0.080), sibutramine 15 mg (−4.5 kg; −8.9 to −0.59), nizatidine 300 mg (−3.0 kg; −5.9 to −0.23) and metformin 1000 mg (−2.3 kg; −4.6 to −0.0046). There was no effect of duration of follow-up, baseline body weight and, preventive versus therapeutic strategy on weight reduction in AIWG.

Conclusion

Metformin 750 mg with lifestyle modification was the most effective treatment for AIWG, followed by topiramate 200 mg, metformin 750 mg, and topiramate 100 mg with moderate certainty of evidence.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对抗精神病药物诱发的精神分裂症患者体重增加的药物干预:网络荟萃分析
目的 抗精神病药物诱发的体重增加(AIWG)是第一代和第二代抗精神病药物治疗的一个重要但经常被忽视的不良反应,它可能导致心血管功能紊乱。本网络荟萃分析(NMA)旨在评估和比较现有治疗方案对抗精神病药物引起的体重增加(AIWG)的影响。方法通过在MEDLINE/PubMed、Embase、Scopus、Cochrane数据库和临床试验登记处进行文献检索,从68项相关临床试验中提取数据。采用随机效应贝叶斯近似模型对体重从基线开始变化的干预效果进行了汇总。建立网络图,运行一致性模型,进行节点拆分分析,根据 SUCRA 评分对治疗方法进行排序,并将疗程、基线体重和治疗策略作为预测变量进行元回归。结果显示体重显著下降的药物按效应大小排序包括:西布曲明 10 毫克(-8.0 千克;-16.4)、二甲双胍 750 毫克(-5.7 千克;-9.3 至-2.1)、托吡酯 100 毫克(-5.7 千克;-8.8 至-2.5)、托吡酯 50 毫克(-5.2 千克;-10 至-0.57)、利拉鲁肽 1.8 毫克(-5.2 kg; -10., -0.080)、西布曲明 15 mg (-4.5 kg; -8.9 to -0.59)、尼扎替丁 300 mg (-3.0 kg; -5.9 to -0.23)和二甲双胍 1000 mg (-2.3 kg; -4.6 to -0.0046)。结论:二甲双胍750毫克配合生活方式调整是治疗AIWG最有效的方法,其次是托吡酯200毫克、二甲双胍750毫克和托吡酯100毫克,证据的确定性为中等。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
General hospital psychiatry
General hospital psychiatry 医学-精神病学
CiteScore
9.60
自引率
2.90%
发文量
125
审稿时长
20 days
期刊介绍: General Hospital Psychiatry explores the many linkages among psychiatry, medicine, and primary care. In emphasizing a biopsychosocial approach to illness and health, the journal provides a forum for professionals with clinical, academic, and research interests in psychiatry''s role in the mainstream of medicine.
期刊最新文献
Prevalence of reversible visual impairments and their association with the psychiatric illness severity among inpatients with psychotic disorders. Mental health effects of neurosurgery for drug-resistant epilepsy. Cancer screening among people with schizophrenia before and after the COVID-19 pandemic in Ontario, Canada: Retrospective cohort study. The effects of tele-based interventions for depression and anxiety symptoms in patients with Chronic Obstructive Pulmonary Disease (COPD): A systematic review and meta-analysis Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1